Loading institutional data...
Loading institutional data...
Held by 4,193 of 5,944 reporting institutions (100th percentile) — extremely crowded.
Data as of Q1 2026
Loading snapshot...
Loading financials...
Loading valuation...
Loading quality & risk...
Loading dividends & returns...
Loading capital allocation...
Loading debt & leverage...
Loading performance...
Loading peer comparison...
Loading ownership map...
Loading crowding analysis...
Loading conviction analysis...
Loading buy/sell flow...
Loading ownership trends...
Loading top holders...
Loading top holders...
Total shares institutions bought (green) vs sold (red) each quarter across all holders.
Inferred from quarter-over-quarter change in each fund's 13F position (new stakes count as buys, exits as sells). Not tick-level trades.
How management deployed cash over 10 years — and what it earned on reinvestment.
A cash-return story — far more went to shareholders than back into the business (mature, low-reinvestment).
Insufficient data. Current ROIC on all capital: 30%. Rough measure (includes maintenance capex).
Cash uses aggregated from the SEC cash-flow statement over 10 fiscal years. "Return on reinvestment" is a rough proxy — operating-income change ÷ cumulative CapEx + M&A — and includes maintenance capex. Educational — not a recommendation.
How much the company owes, how it's trended, and how comfortably it's serviced.
Cash of $7.3B covers the $781M due within a year 9.3× over. Scheduled principal only (excludes interest & revolver draws). As of 2024-12-31 (10-K).
Insufficient EBITDA/debt history.
Green ≤ 1.5× · amber ≤ 3× · red > 3× (leverage relative to cash earnings).
Interest expense isn't separately reported — often netted into “other income (expense), net.” Effective rate ~2.1% on $42.5B of debt.
Cash of $7.3B fully covers short-term debt of $1.6B.
Mostly long-term debt (balance-sheet current vs non-current split). See the maturity ladder above for the year-by-year repayment schedule.
Debt, cash, interest and equity from the SEC balance sheet & income statement. Effective rate = interest ÷ average debt. Maturity ladder from the SEC long-term-debt repayment schedule. Educational — not a recommendation.
EOD close · as of 2026-09-17
How a revenue dollar becomes profit — FY2025
Each value shows its share of revenue below it (common-size).
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $65.18B 100.0% | $45.04B 100.0% | $34.12B 100.0% | $28.54B 100.0% | $28.32B 100.0% | $24.54B 100.0% | $22.32B 100.0% | $21.49B 100.0% | $19.97B 100.0% | $18.31B 100.0% |
| Cost of Revenue | $11.05B 17.0% | $8.42B 18.7% | $7.08B 20.8% | $6.63B 23.2% | $7.31B 25.8% | $5.48B 22.3% | $4.72B 21.2% | $4.68B 21.8% | $4.45B 22.3% | $4.16B 22.7% |
| Cost of Products | — | — | — | — | — | — | — | — | $6.07B 30.4% | $5.65B 30.9% |
| Research & Development | — | — | — | $7.19B 25.2% | $6.93B 24.5% | $5.98B 24.4% | $5.59B 25.1% | $5.05B 23.5% | $5.10B 25.5% | $5.04B 27.5% |
| Selling, General & Admin | $11.09B 17.0% | $8.59B 19.1% | $7.40B 21.7% | $6.44B 22.6% | $6.43B 22.7% | $6.12B 24.9% | $6.21B 27.8% | $5.98B 27.8% | $5.98B 30.0% | $5.84B 31.9% |
| Interest Expense | $895.0M 1.4% | $781.0M 1.7% | $485.9M 1.4% | $331.6M 1.2% | $339.8M 1.2% | $359.6M 1.5% | $400.6M 1.8% | $242.5M 1.1% | $225.0M 1.1% | $185.2M 1.0% |
| Interest & Investment Income | — | $175.2M 0.4% | $173.6M 0.5% | $62.8M 0.2% | $25.4M 0.1% | $33.0M 0.1% | $80.4M 0.4% | $159.3M 0.7% | $166.4M 0.8% | $107.9M 0.6% |
| Other Income (Expense), net | -$571.0M -0.9% | -$219.0M -0.5% | $97.0M 0.3% | -$320.9M -1.1% | -$201.6M -0.7% | $1.17B 4.8% | $291.6M 1.3% | $145.6M 0.7% | $301.5M 1.5% | $108.8M 0.6% |
| Pretax Income | $25.73B 39.5% | $12.68B 28.2% | $6.55B 19.2% | $6.81B 23.8% | $6.16B 21.7% | $7.23B 29.5% | $5.27B 23.6% | $3.68B 17.1% | $2.30B 11.5% | $3.28B 17.9% |
| Income Tax Expense | $5.09B 7.8% | $2.09B 4.6% | $1.31B 3.9% | $561.6M 2.0% | $573.8M 2.0% | $1.04B 4.2% | $628.0M 2.8% | $529.5M 2.5% | $2.39B 12.0% | $551.4M 3.0% |
| Net Income | $20.64B 31.7% | $10.59B 23.5% | $5.24B 15.4% | $6.24B 21.9% | $5.58B 19.7% | $6.19B 25.2% | $8.32B 37.3% | $3.23B 15.0% | -$204.1M -1.0% | $2.74B 14.9% |
| Per Share | ||||||||||
| EPS (Basic) | $23.00 | $11.76 | $5.82 | $6.93 | $6.15 | $6.82 | $8.93 | $3.14 | $-0.19 | $2.59 |
| EPS (Diluted) | $22.95 | $11.71 | $5.80 | $6.90 | $6.12 | $6.79 | $8.89 | $3.13 | $-0.19 | $2.58 |
| Weighted Avg Shares (Basic) | 897.3M | 900.6M | 900.2M | 901.7M | 907.0M | 907.6M | 931.1M | 1.03B | 1.05B | 1.06B |
| Weighted Avg Shares (Diluted) | 899.3M | 904.1M | 903.3M | 904.6M | 911.7M | 912.5M | 935.7M | 1.03B | 1.05B | 1.06B |
Source: SEC EDGAR XBRL filings (annual, fiscal year). Quarterly flow items are derived from cumulative filings; balance-sheet figures are as-of each period end. Ratios and margins are computed, not reported.
Solve the discounted cash flow backwards, then stress-test the assumptions.
To be worth $1152.44 today, the market must believe free cash flow compounds 42.6%/yr for a decade (off $4.5B normalized FCF).
The market's 42.6% is more optimistic than its 9-yr track record.
2-stage DCF · 0.90B shares · net debt $35.2B
mean 53.0% · volatility σ 134% · implied rate exceeded in 2/9 yrs
Central path = implied 42.6%/yr growth; shaded band = ±1σ (134%) of this company's historical FCF volatility, widening with time. The wider the band, the less certain the growth.
Reverse DCF: rather than guessing a fair value, we solve for the growth the current price implies, then you stress-test the assumptions. Enterprise value of the FCF stream, less net debt, ÷ shares. Educational — not a recommendation.
Is the value real, and is the business safe? Academic scores + earnings quality + solvency, from SEC filings.
Insufficient balance-sheet detail (needs retained earnings, working capital, equity).
Eight indices comparing this year to last (receivables, margins, asset quality, growth, accruals, leverage). Above −1.78 suggests possible manipulation; below −2.22 is clean.
A screen, not proof — high growth alone can raise it.
Cash conversion lags reported earnings — watch accruals. Lower/negative accruals = higher quality (Sloan).
Coverage data unavailable.
F-Score (0–9 fundamental momentum), Altman Z (distress risk), and Beneish M (earnings-manipulation screen) are academic models computed from the SEC filings. Screens and context — educational, not recommendations.
What the company returns to shareholders — and whether it's covered by cash.
The dividend is comfortably covered — only 60% of free cash flow, leaving room to grow it and fund buybacks. Last year: $5.4B dividends + $4.1B buybacks = $9.5B returned on $9.0B FCF.
9 consecutive years of dividend increases · 13%/yr.
Yields use the latest fiscal-year dividends/buybacks over current market cap. Dividends and buybacks from the SEC cash-flow statement; payout coverage vs net income and free cash flow. Educational — not a recommendation.
Top 40 institutional holders — bubble size is position value, color is the move since last quarter. Hover any holder for detail.
Drag any bubble to rearrange · size = dollar value of the position
EOD close · as of 2026-09-17
Nothing notable to watch.
No material risks flagged.
Where each multiple sits in its own 14-yr range · 85th pct blended
Dot = today · shaded = middle 50% · line = median. Lower percentile = cheaper vs its own 14-yr history.
Is the profit real, and how strong is the balance sheet?
FY2025 · every deduction from revenue to net income
DuPont — the three levers
Watch the leverage lever — a chunk of ROE comes from the balance sheet.
What the company owes vs. what it holds
Year-by-year maturities aren't in SEC companyfacts (footnote-only), so this shows the debt/cash structure and net leverage instead.
Latest year: profit growth vs revenue growth
Operating leverage needs meaningful revenue change.
Each line as % of revenue — the trend in color
| % of revenue | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Cost of Revenue | 21.8 | 21.2 | 22.3 | 25.8 | 23.2 | 20.8 | 18.7 | 17.0 |
| R&D | 23.5 | 25.1 | 24.4 | 24.5 | 25.2 | — | — | — |
| SG&A | 27.8 | 27.8 | 24.9 | 22.7 | 22.6 | 21.7 | 19.1 | 17.0 |
| Income Tax | 2.5 | 2.8 | 4.2 | 2.0 | 2.0 | 3.9 | 4.6 | 7.8 |
| Net Income | 15.0 | 37.3 | 25.2 | 19.7 | 21.9 | 15.4 | 23.5 | 31.7 |
Green = margin-favorable vs the row's own range · red = unfavorable.
The metrics that matter, over time
A 30-second read on LLY: price, valuation, headline fundamentals, and an auto-generated scorecard from SEC filings. Flags are rule-based signals, not recommendations.
Total return (dividends reinvested) vs the market, from quarter-end prices.
Above 0 = ahead of the S&P 500 since the window start; below 0 = behind. Rising means it's pulling ahead.
How far the stock fell below its prior peak. Deeper, longer drawdowns = a rougher ride to the same return.
Quarter-end, dividend-adjusted (total return). Beta & volatility from quarterly returns (annualized). Benchmark is the S&P 500 (SPY total return). Annual returns compound the quarters ending in each calendar year; the first and last years in a window may be partial. Past performance doesn't predict future results.
Ranked against 1085 sector peers with collected financials. Valuation from latest close × latest fiscal-year fundamentals; 13F conviction as of 2026-03-31.
Percentile is “goodness” within the peer set (100 = best). For valuation and leverage that means cheaper / less-levered ranks higher.
| Company | Mkt cap ▼ | P/E | EV/EBITDA | P/S | Rev gr | Gross | Net | ROE | ROIC | Net D/EBITDA | 13F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| BCAX | $1.24T | — | — | — | — | — | — | -34.4% | -34.4% | — | 143 |
| LLY | $1.03T | 50.2× | — | 15.9× | 44.7% | 83.0% | 31.7% | 77.8% | 29.9% | — | 4,193 |
| AKTX | $894.1B | — | — | — | — | — | — | -61.1% | -61.1% | — | 1 |
| JNJ | $650.5B | 24.5× | — | 6.9× | 6.0% | 67.9% | 28.5% | 32.9% | 20.7% | — | 4,451 |
| ABBV | $467.1B | 111.9× | 33.4× | 7.6× | 8.6% | 70.2% | 6.9% | -129% | 6.6% | 4.2× | 3,895 |
| MRK | $368.2B | 20.2× | — | 5.7× | 1.3% | 74.8% | 28.1% | 34.7% | 17.9% | — | 3,594 |
| UNH | $339.9B | 28.4× | 19.7× | 0.8× | 11.8% | 88.7% | 2.7% | 12.0% | 6.8% | 3.9× | 2,891 |
| AZN | $257.7B | — | — | — | — | — | — | — | — | — | 1,248 |
| TMO | $248.2B | 37.1× | 31.9× | 5.6× | 3.9% | — | 15.0% | 12.6% | 7.0% | 4.9× | 2,481 |
| AMGN | $204.6B | 26.7× | 17.6× | 5.6× | 10.0% | 67.2% | 21.0% | 89.1% | 12.2% | 3.8× | 3,014 |
| GILD | $187.3B | 22.3× | 20.4× | 6.4× | 2.4% | 78.8% | 28.9% | 37.5% | 17.9% | 2.4× | 2,218 |
| ABT | $178.0B | 27.5× | 19.2× | 4.0× | 5.7% | 56.4% | 14.7% | 12.5% | 10.0% | 1.4× | 2,964 |
| PFE | $157.1B | 20.3× | — | 2.5× | -1.6% | 74.3% | 12.4% | 9.0% | 5.1% | — | 2,838 |
| DHR | $150.2B | 42.1× | 31.0× | 6.1× | 2.9% | 59.1% | 14.7% | 6.9% | 5.1% | 3.4× | 2,083 |
| ISRG | $136.2B | 48.7× | 37.5× | 13.5× | 20.5% | 66.0% | 28.4% | 16.0% | 16.0% | — | 2,190 |
| VRTX | $131.1B | 33.7× | 28.8× | 10.9× | 8.9% | 86.2% | 32.9% | 21.2% | 21.2% | — | 1,609 |
| BMY | $127.8B | 18.2× | — | 2.6× | -0.2% | 71.1% | 14.6% | 38.2% | 11.1% | — | 2,431 |
| MDT | $118.8B | 24.9× | 12.6× | 3.3× | 8.4% | 65.0% | 13.2% | 9.7% | 9.4% | 0.2× | 2,114 |
| CVS | $114.7B | 64.9× | 11.5× | 0.3× | 7.8% | 45.0% | 0.4% | 2.4% | 2.4% | 0.0× | 1,795 |
| SYK | $107.1B | 33.4× | 18.4× | 4.3× | 11.2% | 64.0% | 12.9% | 14.5% | 8.5% | 2.5× | 2,196 |
| MCK | $102.5B | 22.9× | 16.2× | 0.3× | 12.4% | 3.6% | 1.2% | -219% | 109% | 1.0× | 1,946 |
| HCA | $96.4B | 15.1× | — | 1.3× | 7.1% | — | 9.0% | -113% | 16.8% | — | 1,346 |
| ELV | $91.4B | 16.4× | 15.5× | 0.5× | 12.5% | 89.4% | 2.8% | 12.9% | 7.6% | 4.2× | 1,397 |
| REGN | $82.6B | 19.0× | 19.8× | 5.8× | 1.0% | — | 31.4% | 14.4% | 13.6% | 0.5× | 1,336 |
| CI | $72.7B | 12.4× | 5.5× | 0.3× | 11.2% | 21.8% | 2.2% | 14.3% | 14.1% | 0.0× | 1,583 |
Peers = companies sharing LLY's sector (Healthcare) with collected SEC financials. Multiples use the most recent end-of-day close and latest fiscal-year fundamentals (trailing, not forward). Missing cells mean the peer never reported that line item, has no collected price, or has a non-positive denominator. Not investment advice.